Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Cheung

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Future Oncology (London, England)|May 17, 2019
Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study designDaniel Vt Catenacci, Anteneh Tesfaye, Mohamed Tejani, et al.
Optics Express|April 4, 2015
Polarizing ytterbium-doped all-solid photonic bandgap fiber with ~1150µm(2) effective mode areaFanting Kong, Guancheng Gu, Thomas W Hawkins, et al.
Anticancer Research|April 4, 2008
Prognostic value of the androgen receptor and its coactivators in patients with D1 prostate cancerRyutaro Mori, Qingcai Wang, Marcus L Quek, et al.
Clinical Genitourinary Cancer|February 14, 2009
Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trialEric Cheung, Jacek Pinski, Tanya Dorff, et al.
Biological Reviews of the Cambridge Philosophical Society|September 23, 2014
The return of metabolism: biochemistry and physiology of the pentose phosphate pathwayAnna Stincone, Alessandro Prigione, Thorsten Cramer, et al.
Human Psychopharmacology|January 18, 2018
Consensus statements on the clinical understanding and use of milnacipran in Hong KongWing King Lee, Kwok Leung Au Yeung, Ho Bun Lam, et al.
Blood|April 29, 2018
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphomaAnn S LaCasce, R Gregory Bociek, Ahmed Sawas, et al.
JAMA Oncology|February 10, 2022
Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical TrialNicholas J Vogelzang, Tomasz M Beer, Winald Gerritsen, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Future Oncology (London, England)|May 17, 2019
Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study designDaniel Vt Catenacci, Anteneh Tesfaye, Mohamed Tejani, et al.
Optics Express|April 4, 2015
Polarizing ytterbium-doped all-solid photonic bandgap fiber with ~1150µm(2) effective mode areaFanting Kong, Guancheng Gu, Thomas W Hawkins, et al.
Anticancer Research|April 4, 2008
Prognostic value of the androgen receptor and its coactivators in patients with D1 prostate cancerRyutaro Mori, Qingcai Wang, Marcus L Quek, et al.
Clinical Genitourinary Cancer|February 14, 2009
Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trialEric Cheung, Jacek Pinski, Tanya Dorff, et al.
Biological Reviews of the Cambridge Philosophical Society|September 23, 2014
The return of metabolism: biochemistry and physiology of the pentose phosphate pathwayAnna Stincone, Alessandro Prigione, Thorsten Cramer, et al.
Human Psychopharmacology|January 18, 2018
Consensus statements on the clinical understanding and use of milnacipran in Hong KongWing King Lee, Kwok Leung Au Yeung, Ho Bun Lam, et al.
Blood|April 29, 2018
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphomaAnn S LaCasce, R Gregory Bociek, Ahmed Sawas, et al.
JAMA Oncology|February 10, 2022
Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical TrialNicholas J Vogelzang, Tomasz M Beer, Winald Gerritsen, et al.
Pageof 3